Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum

In situ radioligand binding and quantitative autoradiography have been used to measure the density of striatal D1-like, D2-like, and GABAA receptors in rats treated with haloperidol at 0.01 or 0.1 mg/kg/ day or chlorpromazine, olanzapine or clozapine at 0.1 or 1.0 mg/kg/day for 1, 3 or 7 months. [3H...

Full description

Saved in:
Bibliographic Details
Published in:Life sciences (1973) 2001-08, Vol.69 (11), p.1257-1268
Main Authors: Dean, B, Hussain, T, Scarr, E, Pavey, G, Copolov, D L
Format: Article
Language:English
Subjects:
Animals
Antipsychotic Agents - pharmacology
Benzamides - metabolism
Benzazepines - metabolism
Benzodiazepines
Chlorpromazine - pharmacology
Clozapine - pharmacology
Corpus Striatum - drug effects
Corpus Striatum - metabolism
Dose-Response Relationship, Drug
Haloperidol - pharmacology
Male
Muscimol - metabolism
Olanzapine
Pirenzepine - analogs & derivatives
Pirenzepine - pharmacology
Rats
Rats, Sprague-Dawley
Receptors, Dopamine D2 - metabolism
Receptors, GABA-A - metabolism
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In situ radioligand binding and quantitative autoradiography have been used to measure the density of striatal D1-like, D2-like, and GABAA receptors in rats treated with haloperidol at 0.01 or 0.1 mg/kg/ day or chlorpromazine, olanzapine or clozapine at 0.1 or 1.0 mg/kg/day for 1, 3 or 7 months. [3H]SCH23390 binding to D1-like receptors was not changed by any drug treatments. There were significant increases in [3H]nemonapride binding to D2-like receptors at different time points due to treatment with haloperidol, chlorpromazine and olanzapine. By contrast, treatment with clozapine and olanzapine caused a time-dependent decrease in [3H]muscimol binding to the GABAA receptor. These data suggest that treatment with atypical antipsychotic drugs, but not typical antipsychotic drugs, affect striatal GABAergic neurons. In addition, it would appear that clozapine might be unique in that it does not increase dopamine-D2 like receptor density at doses which would be predicted to have antipsychotic effects in humans. The extent to which such changes are involved in the therapeutic effects of drugs such as olanzapine and clozapine remains to be determined.
ISSN:0024-3205
DOI:10.1016/S0024-3205(01)01214-0